Adjuvant high-dose interferon-{alpha} for resected melanoma in a patient with HIV infection.

Adjuvant interferon (IFN)-alpha remains the standard adjuvant therapy for intermediate and high-risk melanoma after definitive surgical resection. Data addressing the role and safety of adjuvant immunotherapy in HIV-infected patients with melanoma are lacking. We report on an HIV(+) patient who received IFN-alpha as adjuvant treatment for high-risk melanoma. To our knowledge, this is the first reported case of such an approach.

[1]  M. Ernstoff,et al.  Interferon Alfa-2b Adjuvant Therapy of High-Risk Resected Cutaneous Melanoma: The Eastern Cooperative Oncology Group Trial EST 1684 , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  A. Hauschild,et al.  Surgery and radiotherapy in the treatment of cutaneous melanoma , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  Myles G Cockburn,et al.  Increasing burden of melanoma in the United States. , 2009, The Journal of investigative dermatology.

[4]  Judith N. Mandl,et al.  Divergent TLR7 and TLR9 signaling and type I interferon production distinguish pathogenic and nonpathogenic AIDS virus infections , 2008, Nature Medicine.

[5]  P. Sullivan,et al.  Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003. , 2008, Annals of internal medicine.

[6]  F. Barré-Sinoussi,et al.  Plasmacytoid Dendritic Cell Dynamics and Alpha Interferon Production during Simian Immunodeficiency Virus Infection with a Nonpathogenic Outcome , 2008, Journal of Virology.

[7]  A. Jemal,et al.  Cancer Statistics, 2008 , 2008, CA: a cancer journal for clinicians.

[8]  J. Kirkwood,et al.  Interferon-α as adjuvant therapy for melanoma: An individual patient data meta-analysis of randomised trials , 2007 .

[9]  M. Sulkowski,et al.  Therapeutic issues in HIV/HCV-coinfected patients , 2007, Journal of viral hepatitis.

[10]  J. Herbeuval,et al.  HIV-1 immunopathogenesis: how good interferon turns bad. , 2007, Clinical immunology.

[11]  F. D. De Rosa,et al.  Antiretroviral activity of pegylated interferon alfa-2a in patients co-infected with HIV/hepatitis C virus. , 2007, The Journal of antimicrobial chemotherapy.

[12]  D. McCready,et al.  Systematic review of systemic adjuvant therapy for patients at high risk for recurrent melanoma , 2006, Cancer.

[13]  T. Maurer,et al.  Cutaneous malignancy and human immunodeficiency virus disease. , 2006, Journal of the American Academy of Dermatology.

[14]  V. Soriano,et al.  New paradigms in the management of HIV and hepatitis C virus coinfection , 2005, Current opinion in infectious diseases.

[15]  M. Weichenthal,et al.  Malignant Melanoma and HIV Infection – Aggressive Course despite Immune Reconstitution , 2004, Oncology Research and Treatment.

[16]  Michael B Atkins,et al.  Management of cutaneous melanoma. , 2004, The New England journal of medicine.

[17]  J. Manola,et al.  A Pooled Analysis of Eastern Cooperative Oncology Group and Intergroup Trials of Adjuvant High-Dose Interferon for Melanoma , 2004, Clinical Cancer Research.

[18]  V. Sondak,et al.  Pros and cons of adjuvant interferon in the treatment of melanoma. , 2003, The oncologist.

[19]  Donald R. Miller,et al.  Melanoma incidence and mortality among US whites, 1969-1999. , 2002, JAMA.

[20]  D. Paraskevis,et al.  Low-dose IFN-alpha monotherapy in treatment-naive individuals with HIV-1 infection: evidence of potent suppression of viral replication. , 2001, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[21]  D. Haas,et al.  A randomized trial of interferon alpha therapy for HIV type 1 infection. , 2000, AIDS research and human retroviruses.

[22]  M. Weinstock,et al.  Do sunscreens increase or decrease melanoma risk: an epidemiologic evaluation. , 1999, The journal of investigative dermatology. Symposium proceedings.

[23]  H. Balfour,et al.  Phase II, randomized, open-label, community-based trial to compare the safety and activity of combination therapy with recombinant interferon-α2B and zidovudine versus zidovudine alone in patients with asymptomatic to mildly symptomatic HIV infection , 1999 .

[24]  D. Richman,et al.  Safety and antiviral activity of combination therapy with zidovudine, zalcitabine, and two doses of interferon-alpha2a in patients with HIV. AIDS Clinical Trials Group Study 197. , 1997, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[25]  P. Reiss,et al.  High-dose interferon-alpha2a exerts potent activity against human immunodeficiency virus type 1 not associated with antitumor activity in subjects with Kaposi's sarcoma. , 1997, The Journal of infectious diseases.

[26]  G. Weverling,et al.  Zidovudine and interferon-alpha combination therapy versus zidovudine monotherapy in subjects with symptomatic human immunodeficiency virus type 1 infection. , 1994, The Journal of infectious diseases.

[27]  R. Weinstein,et al.  Zidovudine-Interferon-α Combination Therapy in Patients with Advanced Human Immunodeficiency Virus Type 1 Infection: Biphasic Response of p24 Antigen and Quantitative Polymerase Chain Reaction , 1992 .

[28]  R. Pollard,et al.  Metabolic interaction of recombinant interferon-beta and zidovudine in AIDS patients. , 1991, Journal of interferon research.

[29]  J. Nielsen,et al.  Suppression of p24 antigen in sera from HIV-infected individuals with low-dose alpha-interferon and zidovudine: a pilot study. , 1989, AIDS.

[30]  M. Baseler,et al.  ANTI-RETROVIRAL EFFECTS OF INTERFERON-α IN AIDS-ASSOCIATED KAPOSI'S SARCOMA , 1988, The Lancet.

[31]  C. Boucher,et al.  CLINICAL AND VIROLOGICAL EFFECTS OF HIGH-DOSE RECOMBINANT INTERFERON-α IN DISSEMINATED AIDS-RELATED KAPOSI'S SARCOMA , 1988, The Lancet.

[32]  S. Mocellin,et al.  Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis. , 2010, Journal of the National Cancer Institute.

[33]  R. Weinstein,et al.  Zidovudine-interferon-alpha combination therapy in patients with advanced human immunodeficiency virus type 1 infection: biphasic response of p24 antigen and quantitative polymerase chain reaction. , 1992, The Journal of infectious diseases.

[34]  J. Metcalf,et al.  Anti-retroviral effects of interferon-alpha in AIDS-associated Kaposi's sarcoma. , 1988, Lancet.